Donor cell–derived myelodysplastic syndrome: From recipient diagnosis to donor trace-back
Clinical Hematology International: Case Reports · 20.07.2026 · 1 (3)
DOI: 10.46989/001c.164905 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Hematology International: Case Reports, online erschienen am 20.07.2026. Verfasst von Joana F. Ribeiro und 5 weiteren Autor:innen. Die Arbeit nennt 5 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Donor cell–derived hematologic neoplasms (DCHN) are rare but severe complications following allogeneic hematopoietic stem cell transplantation (allo-HSCT). Their diagnosis is challenging and requires integration of cytogenetic, molecular and chimerism studies. Beyond recipient management, these cases raise important concerns regarding donor trace-back and biovigilance procedures. Case Presentation We report the case of a male patient with severe acquired aplastic anemia who underwent allo-HSCT from a fully matched unrelated donor. The patient achieved complete donor chimerism and remained clinically stable. Nearly a decade after transplantation, bone marrow examination showed 5–6% myeloid blasts with dysplasia. Chimerism studies confirmed complete donor origin (>99.8%), supporting the diagnosis of donor cell–derived myelodysplastic syndrome with excess blasts (MDS-EB1). Following the recipient’s diagnosis, the donor was recalled through the national donor registry. Clinical evaluation revealed no evidence of hematologic malignancy and no constitutional symptoms. Laboratory investigation revealed mild transient leukopenia, neutropenia, lymphopenia, macrocytosis, and folate deficiency, with subsequent normalization after folic acid supplementation. Throughout the process, strict donor–recipient anonymity and confidentiality were maintained. The recipient subsequently underwent a second allo-HSCT and remains in remission. The case was reported to the Portuguese biovigilance system as a severe adverse reaction (SAR) associated with hematopoietic cell transplantation.
Conclusion
This case highlights the diagnostic complexity of DCHN and the importance of integrating chimerism studies and molecular techniques for accurate diagnosis. It also emphasizes the relevance of structured donor trace-back procedures while preserving donor–recipient confidentiality.
Zitieren
APA
Ribeiro, J. F., Vieira, L., Lopes, S., Marcelino, R., Bolotinha, C., & Roncon, S. (2026). Donor cell–derived myelodysplastic syndrome: From recipient diagnosis to donor trace-back. Clinical Hematology International: Case Reports, 1(3). https://doi.org/10.46989/001c.164905
Vancouver
Ribeiro JF, Vieira L, Lopes S, Marcelino R, Bolotinha C, Roncon S. Donor cell–derived myelodysplastic syndrome: From recipient diagnosis to donor trace-back. Clinical Hematology International: Case Reports. 2026;1(3). doi:10.46989/001c.164905
BibTeX
@article{Ribeiro2026,
author = {Ribeiro, Joana F. and Vieira, Lúcia and Lopes, Sara and Marcelino, Rute and Bolotinha, Catarina and Roncon, Susana},
title = {Donor cell–derived myelodysplastic syndrome: From recipient diagnosis to donor trace-back},
journal = {Clinical Hematology International: Case Reports},
year = {2026},
volume = {1},
number = {3},
doi = {10.46989/001c.164905}
}
EUVIMED